Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-002769.pdf
0001179110-17-002769.rtf
0001179110-17-002769.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-002770.pdf
0001179110-17-002770.rtf
0001179110-17-002770.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0001193805-17-000188.pdf
0001193805-17-000188.rtf
0001193805-17-000188.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000315066-17-001482.pdf
0000315066-17-001482.rtf
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000921895-17-000347.pdf
0000921895-17-000347.rtf
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0001144204-17-008995.pdf
0001144204-17-008995.rtf
0001144204-17-008995.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0001193125-17-040526.pdf
0001193125-17-040526.rtf
0001193125-17-040526.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000899243-17-003295.pdf
0000899243-17-003295.rtf
0000899243-17-003295.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000899243-17-003297.pdf
0000899243-17-003297.rtf
0000899243-17-003297.xls
SC 13G

A statement of beneficial ownership of common stock by certain persons

 View HTML
0000215457-17-002178.pdf
0000215457-17-002178.rtf